Clinical Trials

Find trials by condition, location & phase

Drug Monographs

Browse drug monographs and information

Explore organizations and their profiles

Latest updates on trials and healthcare

Approved products by global authorities

AI-Powered Research

Discover powerful insights with advanced AI analysis tools for clinical trials.

Premium Access

Get unlimited access to our comprehensive pharmaceutical database and analytics.

NATIONAL INSTITUTES OF HEALTH

🇺🇸United States

Country: 🇺🇸United States

Ownership: Subsidiary, Private

Established: 1948-01-01

Employees: 1K

Market Cap: -

Website: http://www.nidcr.nih.gov

Clinical Trials

Treatment of Uterine Fibroids With the Selective Progesterone Receptor Modulator CDB-2914

Phase 2

Completed

Conditions: Leiomyoma

Interventions: Drug: ulipristal acetate 20 mg
Drug: placebo
Drug: ulipristal acetate 10 mg

First Posted Date: 2006-02-10

Last Posted Date: 2024-07-15

Lead Sponsor: National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)

Target Recruit Count: 72

Registration Number: NCT00290251

Locations: 🇺🇸
NIH Clinical Center, Bethesda, Maryland, United States
🇺🇸
National Institutes of Health Clinical Center, 9000 Rockville Pike, Bethesda, Maryland, United States

Glucocorticoid-induced Osteopenia in Children

Completed

Conditions: Crohn's Disease
Nephrotic Syndrome

First Posted Date: 2006-02-09

Last Posted Date: 2010-03-02

Lead Sponsor: National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)

Target Recruit Count: 550

Registration Number: NCT00289328

Locations: 🇺🇸
Children's Hospital of Philadelphia, Philadelphia, Pennsylvania, United States

Natural History Study of Moles and Suspicious Melanoma

Completed

Conditions: Primary Cutaneous Melanoma
Acquired Melanocytic Nevi
Melanocytic Nevi

First Posted Date: 2006-02-08

Last Posted Date: 2017-07-02

Lead Sponsor: National Cancer Institute (NCI)

Target Recruit Count: 20

Registration Number: NCT00288938

Locations: 🇺🇸
National Institutes of Health Clinical Center, 9000 Rockville Pike, Bethesda, Maryland, United States

Allopurinol for Renal Transplant Associated Hypertension in Children

Phase 1

Withdrawn

Conditions: Hypertension
Renal Transplant

Interventions: Drug: Placebo
Drug: Allopurinol

First Posted Date: 2006-02-07

Last Posted Date: 2017-09-13

Lead Sponsor: National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)

Registration Number: NCT00288171

Locations: 🇺🇸
Texas Children's Hospital, Houston, Texas, United States

Bowman-Birk Inhibitor Concentrate in Preventing Cancer in Healthy Men

Phase 1

Completed

Conditions: Unspecified Adult Solid Tumor, Protocol Specific

Interventions: Drug: Bowman-Birk inhibitor concentrate
Other: placebo

First Posted Date: 2006-02-07

Last Posted Date: 2013-05-03

Lead Sponsor: National Cancer Institute (NCI)

Target Recruit Count: 20

Registration Number: NCT00287833

Locations: 🇺🇸
Abramson Cancer Center of The University of Pennsylvania, Philadelphia, Pennsylvania, United States

3-AP and Radiation Therapy in Treating Patients With Stage III Pancreatic Cancer That Cannot Be Removed By Surgery

Phase 1

Completed

Conditions: Pancreatic Adenocarcinoma
Stage III Pancreatic Cancer AJCC v6 and v7

Interventions: Radiation: 3-Dimensional Conformal Radiation Therapy
Drug: Triapine

First Posted Date: 2006-02-07

Last Posted Date: 2017-08-18

Lead Sponsor: National Cancer Institute (NCI)

Target Recruit Count: 30

Registration Number: NCT00288093

Locations: 🇺🇸
Ohio State University Comprehensive Cancer Center, Columbus, Ohio, United States

Primary Prevention of Hypertension in Obese Adolescents

Phase 2

Completed

Conditions: Obesity
Pre-Hypertension
Hyperuricemia

Interventions: Drug: Placebo
Drug: Allopurinol
Drug: Probenecid

First Posted Date: 2006-02-07

Last Posted Date: 2017-09-14

Lead Sponsor: National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)

Target Recruit Count: 60

Registration Number: NCT00288158

Locations: 🇺🇸
Texas Children's Hospital, Houston, Texas, United States

Statewide (Rhode Island and Neighboring States) Partnerships for Worksite Weight Management

Phase 2

Completed

Conditions: Overweight
Obesity

Interventions: Behavioral: WOW, Working On Wellness weight management

First Posted Date: 2006-02-07

Last Posted Date: 2013-05-01

Lead Sponsor: National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)

Target Recruit Count: 1700

Registration Number: NCT00288145

Locations: 🇺🇸
Brown University, Providence, Rhode Island, United States

Fenretinide and Rituximab in Treating Patients With B-Cell Non-Hodgkin Lymphoma

Phase 1

Terminated

Conditions: Stage I Adult Diffuse Large Cell Lymphoma
Stage I Small Lymphocytic Lymphoma
Stage II Adult Hodgkin Lymphoma
Stage III Adult Diffuse Large Cell Lymphoma
Stage III Mantle Cell Lymphoma
Stage IV Adult Diffuse Large Cell Lymphoma
B-cell Chronic Lymphocytic Leukemia
Contiguous Stage II Adult Burkitt Lymphoma
Stage II Marginal Zone Lymphoma
Noncontiguous Stage II Adult Burkitt Lymphoma

Interventions: Drug: fenretinide
Drug: rituximab

First Posted Date: 2006-02-07

Last Posted Date: 2014-10-06

Lead Sponsor: National Cancer Institute (NCI)

Target Recruit Count: 32

Registration Number: NCT00288067

Locations: 🇺🇸
University of Washington Medical Center, Seattle, Washington, United States

Bortezomib, Paclitaxel, and Carboplatin in Treating Patients With Metastatic Melanoma

Phase 2

Completed

Conditions: Ciliary Body and Choroid Melanoma, Medium/Large Size
Extraocular Extension Melanoma
Iris Melanoma
Recurrent Intraocular Melanoma
Recurrent Melanoma
Stage IV Melanoma

Interventions: Drug: carboplatin
Drug: paclitaxel
Drug: bortezomib

First Posted Date: 2006-02-07

Last Posted Date: 2013-03-05

Lead Sponsor: National Cancer Institute (NCI)

Target Recruit Count: 36

Registration Number: NCT00288041

Locations: 🇺🇸
Mayo Clinic, Rochester, Minnesota, United States

© Copyright 2025. All Rights Reserved by MedPath

Home Terms & Conditions Privacy Policy